Current Problems in Cardiology
Volume 35, Issue 8 , Pages 384-446 , August 2010

Alternative Strategies for the Management of Chronic Stable Angina

References 

  1. Lloyd-Jones D, Abrams R, Cvarnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21–e181
  2. Gibbons RJ, Abrams J, Chatterjee K, et al. Guidelines for the management of patients with chronic stable angina: a report of the ACC/AHA Task Force on Practice guidelines. J Am Coll Cardiol. 2007;50(23):2264–2274
  3. BARI 2D Study GroupFrye RL, August P, et al. The Bari-2D Study Group (A randomized trial of therapies for type 2 diabetres and coronary artery disease). N Engl J Med. 2009;360:2503–2515
  4. Herberden W. Some account of disorder of the breast. Med Trans R Coll Phys (Lond). 1772;2:59–67
  5. Herberden W. Commentaries on the history and care of disease. In: London: T Payne; 1802;
  6. White PD. Angina pectoris: historical background. In:  Paul O editors. Angina Pectoris. vol 1:New York: Medcom Publishing Group; 1974;
  7. Diamond GA, Staniloff HM, Forrester JS, et al. Computer-assisted diagnosis in the noninvasive evaluation of patients with suspected coronary disease. J Am Coll Cardiol. 1983;1:444–455
  8. O'Rourke RA, Hochman JS, Cohen MC, et al. New approaches to diagnosis and management of unstable angina and non-St-segment elevation myocardial infarction. Arch Intern Med. 2001;161:674–682
  9. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary artery disease. N Engl J Med. 1979;300:1350–1358
  10. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification, pathophysiology, epidemiology, imaging methods and clinical implications. Circulation. 1996;94:1175–1192
  11. O'Rourke R, Brundage B, Froelicher V, et al. American College of Cardiology/American Heart Association consensus document on electron beam computed tomography for the diagnosis of coronary artery disease (Committee on Electron Beam Computer Tomography). Circulation. 2000;20:126–140
  12. Detrano RC, Duherty TM, Davies MJ, et al. Predicting coronary events with coronary calcium: pathophysiologic and clinical problems. Curr Probl Cardiol. 2000;25:369–404
  13. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA Writing Committee to Update the 2000 expert consensus document on electron beam computed tomography, developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2007;49(3):378–402
  14. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol. 2002;41:160–168http://www.acc.org/qualityandscience/clinical/guidelines/exercise/exercise_cleanAccessed October 17, 2002
  15. Froelicher VF, Lehmann KG, Thomas R, et al. The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction (Veterans Affairs Cooperative Study in Health services 016 (QUEXTA) Study Group, quantitative exercise testing and angiography). Ann Intern Med. 1998;128:965–974
  16. Froelicher V, Shetler K, Ashley E. Better decisions through science: exercise testing scores. Curr Probl Cardiol. 2003;28:595–620
  17. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guidelines update for the clinical application of echocardiography. J Am Coll Cardiol. 2003;42:954–970
  18. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC revision of the 1995 guidelines for the clinical use of cardiac radionuclide imaging. J Am Coll Cardiol. 2003;42:1318–1333
  19. Douglas JS, Hurst JW. Limitations of symptoms in the recognition of coronary atherosclerotic heart disease. In:  Hurst JW editors. Update. I. The Heart. vol 3:New York: McGraw-Hill; 1979;
  20. Pupita G, Maseri A, Kaski JC, et al. Myocardial ischemia caused by distal coronary artery constriction in stable angina pectoris. N Engl J Med. 1990;323:514–520
  21. Egashira K, Inou T, Hirooka Y, et al. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;328:1659–1664
  22. Maseri A, Crea F, Kaski JC. Mechanisms of angina pectoris in syndrome X. J Am Coll Cardiol. 1991;17:499–506
  23. Maseri A, Chierchia S, Kaski JC. Mixed angina pectoris. J Cardiol. 1985;56(9):30E–33E
  24. Bortone AS, Hess OM, Eberli FR. Abnormal coronary vasomotion during exercise in patients with normal coronary arteries and reduced coronary flow reserve. Circulation. 1991;83:26–37
  25. Sigwart U, Grbic M, Payot J, et al. Ischemic events during coronary artery balloon occlusion. In:  Rutishauser W,  Roskamm H editor. Silent Myocardial Ischemia. vol 29:Berlin: Springer-Verlag; 1984;
  26. Rocco MB, Barry J, Campbell S, et al. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation. 1987;75:395–400
  27. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA. 1912;59:2015–2020
  28. Crawford NH, Bernstein SJ, diMarco J, et al. ACC/AHA guidelines for ambulatory electrocardiography. Circulation. 1999;34:912–948
  29. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the guidelines for ambulatory electrocardiography): developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol. 1999;34:912–948
  30. Greenland P, laBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–215
  31. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic cardiac ischemia pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation. 1997;95:2037–2043
  32. Hubbard BL, Gibbons RJ, Lapeyre AC, et al. Identification of severe coronary artery disease using simple clinical parameters. Arch Intern Med. 1992;152(2):309–312
  33. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. [Published erratum appears in Circulation 1999;98(2):190] Circulation. 1998;97(6):533–543
  34. Mark DB, Shaw L, Harrell FE, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med. 1991;325:849–853
  35. Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging: a diagnostic tool comes of age. Circulation. 1991;83:363–381
  36. Wagdy HM, Hodge D, Christian TF, et al. Prognostic value of vasodilator myocardial perfusion imaging in patients with left bundle-branch-block. Circulation. 1998;97(16):1563–1570
  37. O'Rourke R, Boden W, Weintraub W, et al. Medical therapy versus percutaneous coronary intervention: implications of the Avert Study and the Courage trial. Curr Pract Med. 1999;2(11):225–227
  38. Final report on the aspirin component of the ongoing physicians' Health Study (Steering Committee of the Physicians' Health Study Research Group). N Engl J Med. 1989;321:129–135
  39. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–965
  40. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without St-segment-elevation. N Engl J Med. 2001;345(7):494–502
  41. Pride YB, Wiviott SD, Buros JL, et al. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess improvement in therapeutic outcomes by optimizing platelet inhibitioN with prasugrel (Triton)-Thrombolysis in Myocardial Infarction (TIMI) 38 subtudy. Am Heart J. 2009;158(3):e21–e26
  42. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of Prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66e9-16
  43. American Heart Association. Updated American Heart Association Statement: Patient Guidance Based on Results of the CHARISMA Trial. American Heart Association, Dallas. March 16 2006;
  44. Khot UN, Nissen SE. Is CURE a cure for acute coronary syndromes? (Statistical versus clinical significance). J Am Coll Cardiol. 2002;40:218–219
  45. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (Caprie). Lancet. 1996;348(9038):1329–1339
  46. Pedersen T, Olsson A, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin Survival Study 4S. Circulation. 1998;97:1453–1460
  47. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001–1009
  48. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  49. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atovastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361:1149–1158
  50. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–1080
  51. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phaze Z of the A to Z trial. JAMA. 2004;292:1307–1316
  52. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  53. La Rosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  54. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the asteroid trial. JAMA. 2006;295:1556–1565
  55. Yusef S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (The Heart Outcomes Prevention Evaluation Study Investigators). N Engl J Med. 2000;342:145–153
  56. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular outcomes in people with diabetes mellitus: results of the HOPE study and micro-HOPE sub-study. Lancet. 2000;355:253–259
  57. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris: results of the International multicenter angina exercise (IMAGE) study. J Am Coll Cardiol. 1996;27(2):311–316
  58. Waysbort J, Meshulam N, Brunner D. Isosorbide-five-mononitrate and atenolol in the treatment of stable exertional angina. Cardiology. 1991;79(suppl 2):19–26
  59. Pepine CJ, Feldman RL, Whittle J, et al. Effect of diltiazem in patients with variant angina: a randomized double-blind trial. Am Heart J. 1981;101(6):719–725
  60. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274(8):620–625
  61. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens. 1997;15:105–115
  62. Cheitlin MD, Hutter AM, Brindis RG, et al. ACC/AHA expert consensus documents: use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol. 1999;33:273–282
  63. Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther. 1994;8(3):489–499
  64. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157(21):2413–2446
  65. Alderman MH, Cohen H, Roque R, et al. Effect of long-acting and short-acting calcium antagonist on cardiovascular outcomes in hypertensive patients. Lancet. 1997;349(9052):594–598
  66. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation. 2002;106:3143–3421
  67. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309–316
  68. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–1382
  69. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
  70. Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the women's health initiative. Ann Epidemiol. 2003;95:S122–S128
  71. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease: Veterans Affairs ACME Investigators. N Engl J Med. 1992;326(1):10–16
  72. Coronary angioplasty versus medical therapy for angina: the second randomised intervention treatment of angina (RITA-2) trial (RITA-2 trial participants). Lancet. 1997;350(9076):461–468
  73. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341(2):70–76
  74. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) investigators. [Published erratum appears in N Engl J Med 1997;336(2):147] N Engl J Med. 1996;335(4):217–225
  75. Campbell AR, Satran D, al Zenovich AG. Enhanced external counterpulsation improves systolic blood pressure in patients with refractory angina. Am Heart J. 2008;156:1217–1222
  76. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and angina episodes. J Am Coll Cardiol. 1999;33:1833–1840
  77. Kumar A, Aronow WS, Vadnerkar A, et al. Effect of enhanced external counterpulsation on clinical symptoms, quality of life, 6-minute walking distance, and echocardiographic measurements of left ventricular systolic and diastolic function after 35 days of treatment and at 1-year follow-up in 47 patients with chronic refractory angina pectoris. Am J Ther. 2009;16:116–118
  78. Cannon RO, Canici PG, Epstein SE. Pathophysiological dilemma of syndrome X. Circulation. 1992;85:883–892
  79. Kaplan MN, Syndromes X. Two too many. J Am Coll Cardiol. 1992;69:1643–1644
  80. Taylor AJ, Villines TC, Stane KEJ, et al. Extended-release niacin or ezetibmibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–2122
  81. Blumenthal RS, Michos ED. The HALTS trial—halting atherosclerosis or halted too early. N Engl J Med. 2009;361:2178–2180
  82. Kastelein JJP, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med. 2009;361:2180–2183

PII: S0146-2806(10)00064-2

doi: 10.1016/j.cpcardiol.2010.05.001

Current Problems in Cardiology
Volume 35, Issue 8 , Pages 384-446 , August 2010

Article Tools

* Image Usage & Resolution